Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Narcotic antagonists in the benzomorphan series

Respiratory, cardiovascular and behavioral effects in dogs

  • 20 Accesses

  • 3 Citations


The behavioral, respiratory and cardiovascular effects of four analgesic antagonists derived from the benzomorphan nucleus have been described. In addition, the ability of these agents to reverse the respiratory, cardiovascular and behavioral depression produced by morphine and meperidine has been reported.

Two of the compounds, 2-allyl-5-ethyl-2′-hydroxy-9-methyl-6,7-benzomorphan (I) and 2-cyclopropylmethyl-2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (IV) proved to be potent antagonists.

The other two, 2-(3,3-dimethylallyl)-2′-hydroxy-5,9-dimethyl-6,7-benzomorphan (II) and 2-(3,3-dimethylallyl)-5-ethyl-2′-hydroxy-9-methyl-6,7-benzomorphan (III), were found to be weak antagonists.

This is a preview of subscription content, log in to check access.


  1. Archer, S., N. F. Albertson, L. S. Harris, A. K. Pierson, J. G. Bird, A. S. Keats, J. Telford, and C. N. Papadopoulous: Narcotic antagonists as analgesics. Science 137, 541 (1962).

  2. DeKornfeld, T. J., and L. Lasagna: WIN 20, 740, a potent new analgesic agent. Fed. Proc. 22, 248 (1963).

  3. Deneau, G. A., and M. H. Seevers: Evaluation of morphine-like physical dependence in the rhesus monkey (macaca mulatta). Addendum 2, Bull. Drug Addiction and Narcotics 1962.

  4. Fraser, H. F., and D. E. Rosenberg: Low addictiveness of two analgesics in the benzomorphan series. Biochem. Pharmacol. Vol. 12, Supplement p. 6 (1963).

  5. Studies on the human addiction liability of 2′-hydroxy-5,9-dimethyl-2-(3,3-dimethylallyl)-6,7-benzomorphan (Win 20, 228): a weak narcotic antagonist. J. Pharmacol. exp. Ther. 143, 149 (1964).

  6. Harris, L. S., and A. K. Pierson: Some narcotic antagonists in the benzomorphan series. Addendum 1, Bull. Drug Addiction and Narcotics 1962.

  7. Some narcotic antagonists in the benzomorphan series. J. Pharmacol. exp. Ther. 143, 141 (1964).

  8. Isbell, H.: Attempted addiction to nalorphine. Fed. Proc. 15, 442 (1956).

  9. Keats, A. S., and J. Telford: Nalorphine, a potent analgesic in man. J. Pharmacol. exp. Ther. 117, 190 (1956).

  10. Studies of analgetic drugs: VIII. a narcotic antagonist analgesic without psychotomimetic effects. J. Pharmacol. exp. Ther. 143, 157 (1964).

  11. Lasagna, L., and H. K. Beecher: The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man. J. Pharmacol. exp. Ther. 112, 356 (1954).

  12. Telford, J., and A. S. Keats: Narcotic-narcotic antagonist mixtures. Anesthesiology 22, 465 (1961).

  13. Unna, K.: Antagonistic effect of N-allyl-normorphine upon morphine. J. Pharmacol. exp. Ther. 79, 27 (1943).

  14. Vivante, A., F. F. Kao, and J. Belford: The effect of nalorphine on the respiration of dogs anesthetized with pentobarbital sodium. J. Pharmacol. exp. Ther. 111, 436 (1954).

Download references

Author information

Additional information

Dedicated to Professor Otto Krayer on his 65th birthday.

With 2 Figures in the Text

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Harris, L.S. Narcotic antagonists in the benzomorphan series. Naunyn-Schmiedebergs Arch 248, 426–436 (1964). https://doi.org/10.1007/BF00246889

Download citation


  • Depression
  • Morphine
  • Cardiovascular Effect
  • Meperidine
  • Potent Antagonist